Clomicalm

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clomipramine hydrochloride

Available from:

Virbac S.A.

ATC code:

QN06AA04

INN (International Name):

Clomipramine

Therapeutic group:

psi

Therapeutic area:

Psychoanaleptics

Therapeutic indications:

As an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

Product summary:

Revision: 18

Authorization status:

odobren

Authorization date:

1998-04-01

Patient Information leaflet

                                15
B. UPUTA O VMP
16
UPUTA O VMP:
CLOMICALM 5 MG TABLETE ZA PSE
CLOMICALM 20 MG TABLETE ZA PSE
CLOMICALM 80 MG TABLETE ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
VIRBAC
1ère avenue – 2065 m – LID
06516 Carros
Francuska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Clomicalm 5 mg tablete za pse
Clomicalm 20 mg tablete za pse
Clomicalm 80 mg tablete za pse
Klomipraminklorid
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
5 mg klomipramin hidroklorid
(odgovara 4,5 mg klomipramina)
20 mg klomipraminklorid
(odgovara 17,9 mg klomipramina)
80 mg klomipraminklorid
(odgovara 71,7 mg klomipramina)
Tableta od 5 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
razdjelnim urezom na obje strane.
Tableta od 20 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
jedne je strane otisak ‘C/G’, a s
druge otisak ‘G/N’ i prorez s obje strane.
Tableta od 80 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
jedne je strane otisak ‘I/I’, s druge
nema otiska, a prorez se nalazi s obje strane.
4.
INDIKACIJA(E)
Kao pomoć u liječenju poremećaja povezanih s razdvajanjem u pasa
koji se očituju destrukcijom i
neodgovarajućom eliminacijom (defekacijom i mokrenjem) i samo u
kombinacijama s tehnikama
bihevioralne modifikacije.
5.
KONTRAINDIKACIJE
Ne primjenjivati u slučaju poznate preosjetljivosti na klomipramin i
srodne tricikličke antidepresive.
Ne primjenjivati u muških rasplodnih pasa.
6.
NUSPOJAVE
17
Clomicalm može vrlo rijetko uzrokovati povraćanje, promjene apetita,
letargiju ili povišenje jetrenih
enzima, što je reverzibilno nakon prekida primjene proizvoda.
Prijavljen je hepatobilijarni poremećaj,
posebice ako je postojao u anamnezi i uz istovremenu primjenu
proizvoda koji se metaboliziraju
putem jetre. Povraćanje se može reducirati primjenom s malom
količinom
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Clomicalm 5 mg tablete za pse
Clomicalm 20 mg tablete za pse
Clomicalm 80 mg tablete za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna tableta Clomicalma sadrži:
DJELATNA TVAR:
Klomipraminklorid
5 mg (odgovara 4,5 mg klomipramina)
Klomipraminklorid
20 mg (odgovara 17,9 mg klomipramina)
Klomipraminklorid
80 mg (odgovara 71,7 mg klomipramina)
POMOĆNE TVARI:
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Tablete.
Tableta od 5 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
razdjelnim urezom na obje strane.
Tableta od 20 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
jedne je strane otisak ‘C/G’, a s
druge otisak ‘G/N’ i prorez s obje strane.
Tableta od 80 mg: smećkasto-siva, ovalno-duguljasta, djeljiva. S
jedne je strane otisak ‘I/I’, s druge
nema otiska, a prorez se nalazi s obje strane.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Pas.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Kao pomoć u liječenju poremećaja povezanih s razdvajanjem u pasa
koji se očituju destrukcijom i
neodgovarajućom eliminacijom (defekacijom i mokrenjem) i samo u
kombinacijama s tehnikama
bihevioralne modifikacije.
4.3
KONTRAINDIKACIJE
Ne primjenjivati u slučaju poznate preosjetljivosti na klomipramin i
srodne tricikličke antidepresive.
Ne primjenjivati u muških rasplodnih pasa.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Neškodljivost i djelotvornost Clomicalma nije utvrđena u pasa koji
teže manje od 1,25 kg ili u onih
mlađih od šest mjeseci.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
3
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE NA ŽIVOTINJAMA
Preporučuje se Clomicalm primijeniti na psima s kardiovaskularnom
disfunkcijom ili epilepsijom s
oprezom i samo nakon procjene omjera koristi i rizika. Zbog njegovih
potencijalnih antikolinergičnih
svojstava, Clomicalm treba uvijek koristiti oprezno u pasa s glaukomom
uskog kuta, smanjenom
pokretljivošću crijeva ili
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-10-2021
Public Assessment Report Public Assessment Report Bulgarian 01-07-2016
Patient Information leaflet Patient Information leaflet Spanish 25-10-2021
Public Assessment Report Public Assessment Report Spanish 01-07-2016
Patient Information leaflet Patient Information leaflet Czech 25-10-2021
Public Assessment Report Public Assessment Report Czech 01-07-2016
Patient Information leaflet Patient Information leaflet Danish 25-10-2021
Public Assessment Report Public Assessment Report Danish 01-07-2016
Patient Information leaflet Patient Information leaflet German 25-10-2021
Public Assessment Report Public Assessment Report German 01-07-2016
Patient Information leaflet Patient Information leaflet Estonian 25-10-2021
Public Assessment Report Public Assessment Report Estonian 01-07-2016
Patient Information leaflet Patient Information leaflet Greek 25-10-2021
Public Assessment Report Public Assessment Report Greek 01-07-2016
Patient Information leaflet Patient Information leaflet English 25-10-2021
Public Assessment Report Public Assessment Report English 01-07-2016
Patient Information leaflet Patient Information leaflet French 25-10-2021
Public Assessment Report Public Assessment Report French 01-07-2016
Patient Information leaflet Patient Information leaflet Italian 25-10-2021
Public Assessment Report Public Assessment Report Italian 01-07-2016
Patient Information leaflet Patient Information leaflet Latvian 25-10-2021
Public Assessment Report Public Assessment Report Latvian 01-07-2016
Patient Information leaflet Patient Information leaflet Lithuanian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-10-2021
Public Assessment Report Public Assessment Report Lithuanian 01-07-2016
Patient Information leaflet Patient Information leaflet Hungarian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 25-10-2021
Public Assessment Report Public Assessment Report Hungarian 01-07-2016
Patient Information leaflet Patient Information leaflet Maltese 25-10-2021
Public Assessment Report Public Assessment Report Maltese 01-07-2016
Patient Information leaflet Patient Information leaflet Dutch 25-10-2021
Public Assessment Report Public Assessment Report Dutch 01-07-2016
Patient Information leaflet Patient Information leaflet Polish 25-10-2021
Public Assessment Report Public Assessment Report Polish 01-07-2016
Patient Information leaflet Patient Information leaflet Portuguese 25-10-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 25-10-2021
Public Assessment Report Public Assessment Report Portuguese 01-07-2016
Patient Information leaflet Patient Information leaflet Romanian 25-10-2021
Public Assessment Report Public Assessment Report Romanian 01-07-2016
Patient Information leaflet Patient Information leaflet Slovak 25-10-2021
Public Assessment Report Public Assessment Report Slovak 01-07-2016
Patient Information leaflet Patient Information leaflet Slovenian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 25-10-2021
Public Assessment Report Public Assessment Report Slovenian 01-07-2016
Patient Information leaflet Patient Information leaflet Finnish 25-10-2021
Public Assessment Report Public Assessment Report Finnish 01-07-2016
Patient Information leaflet Patient Information leaflet Swedish 25-10-2021
Public Assessment Report Public Assessment Report Swedish 01-07-2016
Patient Information leaflet Patient Information leaflet Norwegian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 25-10-2021
Patient Information leaflet Patient Information leaflet Icelandic 25-10-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 25-10-2021

Search alerts related to this product

View documents history